Sharing Our Waldmann Experiences - Passive and Active Immunotherapy of Cancer: A Critical Perspective (NIH Only) |
|
|---|---|
|
|
|
| Launch in standalone player | |
| Air date: | Tuesday, June 19, 2007, 9:30:00 AM |
| Category: | NCI CCR Grand Rounds (NIH Only) |
| Runtime: | 01:56:53 |
| NLM Title: | Sharing our Waldmann experiences : passive and active immunotherapy of cancer : a critical perspective [electronic resource] / Thomas A. Waldmann. |
| Series: | Passive and active immunotherapy of cancer |
| Author: | Waldmann, Thomas. Center for Cancer Research (National Cancer Institute (U.S.)) |
| Publisher: | [Bethesda, Md. : National Institutes of Health, 2007] |
| Other Title(s): | Passive and active immunotherapy of cancer |
| Abstract: | (CIT): A program honoring Dr. Thomas Waldmann Thomas A. Waldmann, M.D., is a brilliant scientist, internationally recognized for his pioneering research and leadership in producing the explosion of knowledge about cytokines and their receptors and in the coming of age of monoclonal antibodies, now a dominant form of immunotherapy. His work has extended from basic molecular and cellular immunology to innovative clinical trials of immunotherapeutic agents against cancer and autoimmune diseases that include monoclonal antibodies and cytokines that he discovered. Over his 50-year career he defined the role of the IL-2/IL-2 receptor system in the life and death of normal and neoplastic lymphocytes. These studies have culminated in the definition of the IL-2 receptor as an exceptionally valuable target for the humanized monoclonal antibody he developed, anti-Tac (daclizumab, Zenapax) in the therapy of leukemia, lymphoma, and autoimmune disease. He co-discovered IL-15 and developed various forms of IL-2/IL-15 receptor directed therapy for leukemia, autoimmune diseases and to prevent allograft rejection. He is currently introducing IL-15 and IL-15 receptor directed therapy for patients with cancer. Dr. Waldmann received his M.D. from Harvard Medical School. He joined the NCI in 1956, and has been Chief of the Metabolism Branch since 1973. His honors include the Ehrlich, Bristol-Myers Squibb, Milken, Abbott and Artois-Baillet Latour Prizes and election to the National Academy of Sciences, American Academy of Arts and Sciences and Institute of Medicine, NAS. |
| Subjects: | Immunotherapy Neoplasms--therapy |
| Publication Types: | Government Publications Lectures |
| NLM Classification: | QZ 266 |
| NLM ID: | 101313565 |
| CIT File ID: | 13908 |
| CIT Live ID: | 6008 |
| Permanent link: | http://videocast.nih.gov/launch.asp?13908 |